International approaches to drug policy examines how the UN treaty regime and national reform experiments shape global narcotics governance. The international drug control system represents one of the oldest areas of international criminal law, with roots extending to the Shanghai Opium Commission of 1909. Over more than a century, the system has evolved from a limited framework targeting opium into a global prohibition regime that classifies hundreds of psychoactive substances, obligates nearly every country to criminalize their non-medical use, and supports an enforcement apparatus spanning interdiction, eradication, prosecution, and incarceration. Yet the twenty-first century has witnessed growing challenges from national experiments with decriminalization, harm reduction, and regulated legalization that test the boundaries of treaty obligations and expose tensions between prohibition and public health evidence. This article, part of the Comparative Criminology section of the broader Criminology resource, examines the international drug control treaty regime, surveys the national reform experiments reshaping it, and evaluates the future of global drug governance in an era of growing policy divergence.
Introduction
The international drug control regime is anchored by three United Nations conventions—the Single Convention on Narcotic Drugs (1961, as amended 1972), the Convention on Psychotropic Substances (1971), and the Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances (1988)—that together establish a prohibition framework requiring signatory states to limit the production, distribution, and use of scheduled substances to medical and scientific purposes and to criminalize their non-medical trafficking and possession. These conventions have been ratified by more than 180 states, making them among the most widely accepted international legal instruments in existence (Bewley-Taylor, 2012).
The system’s near-universal ratification masks growing divergence in national practice. Portugal has decriminalized personal possession of all drugs. The Netherlands tolerates retail cannabis sale through licensed coffee shops. Switzerland, Germany, and Denmark operate heroin-assisted treatment programs. Uruguay, Canada, and more than 20 American states have legalized recreational cannabis. Germany legalized recreational cannabis in 2024. These experiments test whether the prohibition framework can accommodate the diversity of approaches that the comparative evidence supports—a question whose answer will shape the future of global drug governance (Csete et al., 2016).
The Treaty Regime
The Three Conventions
The 1961 Single Convention consolidated earlier treaties and established the scheduling system classifying substances according to perceived danger and medical utility. Schedule I includes drugs deemed to have high abuse potential and limited medical use, such as heroin, cocaine, and cannabis. The Convention requires states to limit cultivation, production, and distribution of scheduled substances to medical and scientific purposes. The International Narcotics Control Board (INCB), established by the Convention, monitors implementation and maintains a system of estimates and statistical returns tracking global production and consumption of controlled substances (Bewley-Taylor, 2012).
The 1971 Convention on Psychotropic Substances extended controls to synthetic substances—amphetamines, barbiturates, benzodiazepines, hallucinogens—not covered by the 1961 Convention. Its scheduling system is less restrictive, reflecting pharmaceutical industry lobbying to maintain flexibility for medicines with both therapeutic and abuse potential. The difference in restrictiveness has been cited as evidence that the regime reflects the economic interests of pharmaceutical-producing countries alongside public health considerations (Room, 2012).
The 1988 Convention strengthened enforcement by requiring states to criminalize drug trafficking, establish mechanisms for international cooperation, and adopt controls on precursor chemicals. Article 3(2) requires states to establish possession for personal consumption as a criminal offense, subject to “constitutional principles and basic concepts” of each state’s legal system. This provision has been interpreted differently: some states view it as requiring criminalization, others argue it permits administrative penalties—a disagreement at the heart of current reform debates (Bewley-Taylor, 2012).
The INCB and Compliance
The INCB issues annual reports assessing the drug control system and identifying concerns. The Board has consistently interpreted the conventions as requiring criminal sanctions for non-medical drug use and has criticized reforms it views as treaty-inconsistent—including cannabis legalization in Uruguay, Canada, and American states, and the Netherlands’ tolerance policy. The Board’s interpretive authority has been questioned by states and scholars who argue that the conventions provide more flexibility than the INCB acknowledges (INCB, 2023).
The Single Convention’s requirement to limit drug use to “medical and scientific purposes” has been interpreted by some as permitting regulated supply systems serving public health objectives, while others argue any non-medical supply violates the Convention’s plain language. The 1988 Convention’s subjection of the personal possession offense to “constitutional principles and basic concepts” has been cited as a basis for decriminalization by several states. The absence of an effective enforcement mechanism means compliance depends on peer pressure, diplomatic engagement, and the normative weight of obligations—not formal sanctions (Room, 2012).
The growing number of departures from the prohibition framework raises questions about the conventions’ continued authority. States that violate or stretch the conventions face no formal consequences, and the INCB’s critical reports have not prevented the expansion of national experiments. The regime may be evolving through practice in ways that formal treaty revision has been unable to achieve—a process with precedents in other areas of international law where treaty obligations have been eroded through non-compliance and reinterpretation rather than formal amendment (Bewley-Taylor, 2012).
National Reform Experiments
Decriminalization Models
Decriminalization—removing criminal penalties for personal possession while maintaining prohibition of production and trafficking—has been adopted in various forms by more than 25 countries. Portugal’s 2001 reform, treating personal possession as an administrative matter and referring individuals to health-oriented dissuasion commissions, is the most extensively studied model. Drug-related mortality, HIV infections among people who inject drugs, and the proportion of drug offenders in prison declined significantly following reform, without appreciable increases in drug use prevalence (Hughes & Stevens, 2010).
Similar findings have been reported from the Czech Republic, where decriminalization of personal possession has been associated with stable or declining use rates. These outcomes support the proposition that criminal sanctions for personal use contribute little to deterrence while generating significant harms—criminal records, incarceration, stigma—that impede treatment, employment, and social reintegration. The comparative evidence suggests decriminalization is most effective when accompanied by investment in treatment, harm reduction, and reintegration services that address the health consequences of drug use (Greenwald, 2009).
Oregon’s Measure 110 (2020) represented the most ambitious American decriminalization experiment. While implementation encountered challenges—insufficient treatment infrastructure, delayed service rollout—the comparative evidence from Portugal demonstrates that decriminalization, when accompanied by adequate service provision, produces outcomes that enforcement-oriented approaches cannot match. The Oregon experience also illustrates the political fragility of drug policy reform: public dissatisfaction with visible drug use led to partial rollback, demonstrating that decriminalization requires not only legal reform but community engagement and investment in the public health infrastructure that makes reform socially sustainable (Csete et al., 2016).
Cannabis Legalization
The legalization of recreational cannabis in Uruguay (2013), Canada (2018), and more than 20 American states represents the most significant departure from the prohibition framework in its history. These experiments replace criminal markets with regulated commercial systems controlling production, distribution, and sale through licensing, taxation, and product safety requirements—an approach the INCB has characterized as a treaty violation (Caulkins, Kilmer, & Kleiman, 2016).
Early evaluations show nuanced results. Adult cannabis use has increased modestly in legalized jurisdictions, while youth use has generally remained stable. Tax revenues have exceeded projections. Cannabis arrests have declined dramatically, reducing racial disparities that characterized prohibition enforcement. However, concerns persist about impaired driving, illicit market persistence for untaxed products, high-potency product emergence, and the development of a concentrated cannabis industry with incentives to promote heavy use (Cerdá et al., 2020).
Canada’s federal framework offers important lessons for regulated market design. The Cannabis Act establishes national production, packaging, and potency standards while allowing provincial retail models. This provides regulatory consistency that the American patchwork of state laws cannot achieve. Germany’s 2024 legalization, emphasizing cannabis social clubs and home cultivation rather than commercial retail, represents yet another regulatory model. The diversity of legalization approaches across jurisdictions creates a natural experiment whose outcomes are informing policy debates globally (Fischer et al., 2020).
Harm Reduction and Public Health
Evidence-Based Interventions
Harm reduction—interventions reducing health, social, and economic harms without requiring abstinence—has become one of the most significant areas of policy divergence between the treaty regime and national practice. Needle exchange programs, opioid substitution therapy, supervised consumption facilities, drug checking services, and naloxone distribution have been implemented in numerous countries with strong evidence of effectiveness in reducing mortality, disease transmission, and associated criminal behavior (Csete et al., 2016).
Switzerland’s heroin-assisted treatment program, initiated in 1994, demonstrated that providing pharmaceutical heroin to chronic users in supervised clinical settings produces significant reductions in illicit use, criminal activity, and health problems, with cost savings exceeding program expenditures. The program’s success led to permanent adoption and replication in Germany, Denmark, the Netherlands, and the United Kingdom. The INCB has accepted heroin-assisted treatment as compatible with the conventions when provided within a medical framework, illustrating that harm reduction can be accommodated within the treaty regime when framed as medical intervention (Rehm et al., 2001).
Supervised consumption facilities—operating in more than 10 countries—provide environments where individuals consume pre-obtained drugs under medical supervision with access to naloxone, health assessments, and treatment referrals. Systematic reviews consistently find that facilities reduce overdose mortality in surrounding areas, decrease public drug use, and facilitate treatment entry. The establishment of authorized facilities in New York City and Rhode Island extended the harm reduction approach to the United States—the country historically most committed to the prohibition paradigm—marking a significant policy shift driven by the urgency of the fentanyl crisis (Potier et al., 2014).
The Opioid Crisis and Policy Acceleration
The opioid crisis has underscored prohibition’s limitations and accelerated harm reduction adoption. The United States experienced more than 100,000 annual overdose deaths by 2021—predominantly involving illicitly manufactured fentanyl—prompting expansion of naloxone access, medication-assisted treatment, and syringe services, though access remains uneven and politically contested. Canada has adopted a more aggressive approach, declaring public health emergencies, expanding supervised consumption, and piloting safer drug supply programs providing pharmaceutical alternatives to contaminated street drugs (Csete et al., 2016).
The crisis also exposed pharmaceutical industry and regulatory failures in generating conditions enabling the epidemic—conditions the treaty regime, designed for illicit drugs, was not equipped to prevent. Overprescription of opioid analgesics, driven by aggressive marketing and inadequate oversight, demonstrated that the distinction between licit and illicit drugs does not map neatly onto the distinction between safe and dangerous use. Countries with stricter marketing regulations and conservative prescribing guidelines experienced less severe crises, providing comparative evidence that upstream regulatory choices significantly influence downstream health outcomes (Kolodny et al., 2015).
The opioid crisis has created political conditions favorable to drug policy reform that were absent for decades. Conservative states in the American South and Midwest—traditionally aligned with punitive drug policies—have adopted harm reduction measures including naloxone distribution and syringe exchange in response to fentanyl deaths devastating their communities. The crisis has demonstrated that drug policy reform can transcend the left-right political divide when the human costs of prohibition become sufficiently visible and personally felt by constituencies across the political spectrum (Csete et al., 2016).
The Political Economy of Drug Control
Institutional Interests and Path Dependence
The persistence of the prohibition paradigm despite growing evidence of its limitations reflects powerful institutional interests that sustain the status quo. Law enforcement agencies, prison systems, drug testing companies, and the military organizations involved in counter-narcotics operations all derive budgets, personnel, and institutional legitimacy from the enforcement of prohibition. The dismantling of prohibition would threaten these institutional interests, creating resistance to reform that is independent of the policy merits of alternative approaches. The comparative evidence reveals that countries where drug enforcement institutions are less politically powerful—Portugal, the Netherlands, Switzerland—have been more successful in implementing evidence-based reforms than countries where enforcement agencies wield significant political influence (Reuter, 2013).
The pharmaceutical industry’s role in the drug control system adds another layer of political economy. The distinction between licit and illicit drugs—which is fundamental to the treaty regime—has been shaped by the economic interests of pharmaceutical companies that profit from the legal manufacture and distribution of psychoactive substances including opioids, benzodiazepines, and stimulants. The opioid crisis exposed the consequences of this arrangement, demonstrating that legal drugs promoted by profit-motivated corporations can cause more harm than the illicit drugs that the prohibition regime was designed to control. Reforming the international drug control system requires attention not only to the regulation of illicit substances but also to the governance of the pharmaceutical industry whose products cause significant harm under the protection of legality (Babor et al., 2018).
The global dimensions of the political economy of drug control reflect inequalities between producing and consuming countries. The costs of prohibition—violence, corruption, environmental degradation, mass incarceration—fall disproportionately on producing and transit countries in Latin America, West Africa, and Southeast Asia, while the benefits of enforcement accrue primarily to consuming countries whose domestic populations experience reduced drug availability at the margin. This distributional inequity has generated growing criticism from Latin American leaders who have called for alternative approaches that distribute the costs and benefits of drug control more equitably across the international community (Youngers & Rosin, 2005).
Civil Society and Reform Advocacy
Civil society organizations have played a critical role in building political support for drug policy reform at both national and international levels. Organizations such as the Global Commission on Drug Policy, the Drug Policy Alliance, Transform Drug Policy Foundation, and the International Drug Policy Consortium have advocated for evidence-based alternatives to prohibition, provided technical expertise to reforming governments, and challenged the prohibition consensus in international forums. The Global Commission—comprising former heads of state, Nobel laureates, and senior officials—has been particularly influential in legitimizing reform advocacy by demonstrating that support for alternatives to prohibition extends to the highest levels of political leadership (Csete et al., 2016).
Academic research has provided the evidence base that reform advocacy draws upon. The Lancet Commission on Drug Policy and Health, systematic reviews of harm reduction effectiveness, and evaluations of national reform experiments have generated a body of evidence that is increasingly difficult for prohibition defenders to dismiss. The translation of academic evidence into policy change requires intermediary organizations that can bridge the gap between research and politics—a function that drug policy reform organizations have performed with growing effectiveness in recent decades (Stevens, 2011).
The media’s role in shaping public attitudes toward drug policy has shifted significantly. Coverage that previously emphasized the threat of drug use and the necessity of enforcement increasingly highlights the human costs of prohibition—mass incarceration, racial disparities, overdose deaths—and the evidence supporting alternative approaches. This shift in media framing has contributed to changing public attitudes, particularly among younger voters, creating political conditions more favorable to reform than at any previous point in the prohibition era. The comparative dimension is significant: countries with media environments that facilitate evidence-based public discourse about drug policy have been more successful in implementing reform than those where sensationalized coverage reinforces prohibitionist attitudes (Chatwin, 2011).
The Future of Global Drug Governance
Reform Pathways
The future of the regime will be shaped by the tension between the conventions’ prohibition framework and growing national departures. Several reform pathways have been proposed: treaty reservations, inter se modifications among like-minded states, and the denunciation-and-re-accession procedure. Bolivia successfully used denunciation and re-accession in 2012 to reserve the right to permit traditional coca chewing, establishing a precedent other states could follow for more extensive reforms (Room, 2012).
The 2016 UNGASS on the World Drug Problem produced an outcome document acknowledging the importance of public health approaches and evidence-based policy—a modest shift from the enforcement-oriented consensus of previous sessions. The 2019 ministerial declaration reaffirmed convention commitment while acknowledging implementation challenges. These diplomatic outcomes reflect the difficulty of achieving consensus within the UN system, where the prohibition paradigm retains strong support from several influential states even as a growing number pursue alternatives (Bewley-Taylor, 2012).
The most likely trajectory is continued de facto pluralism—conventions remaining formally in force while expanding departures accumulate—rather than formal revision. This trajectory risks undermining the regime’s coherence without replacing it with a more evidence-based alternative. But it also allows national experimentation to generate evidence that can eventually inform a more rational international approach. The comparative study of drug policy demonstrates that this tension cannot be resolved through legal interpretation alone; it reflects fundamental disagreements about drug control purposes, criminal law’s role in managing substance use, and the weight given to public health evidence (Room, 2012).
Toward Evidence-Based Governance
The comparative evidence consistently supports the conclusion that punitive prohibition produces worse outcomes than public health approaches across virtually every indicator: drug-related mortality, disease transmission, incarceration rates, racial disparities, corruption, organized crime revenues, and enforcement costs. Countries achieving the best outcomes—Portugal, Switzerland, the Netherlands, Scandinavian countries—have invested most heavily in treatment, harm reduction, and social integration while maintaining criminal penalties for trafficking (Csete et al., 2016).
The translation of evidence into international policy requires overcoming political obstacles that are formidable but not insurmountable. The growing number of reforming countries, accumulating evidence of prohibition’s harms, and fiscal pressures from mass incarceration and the opioid crisis all create conditions favorable to change. The challenge is developing an international framework accommodating diversity while maintaining coordination mechanisms for precursor chemical control, anti-trafficking enforcement, and public health monitoring that international cooperation uniquely provides (Bewley-Taylor, 2012).
The future of global drug governance lies not in perpetuating a prohibition consensus that no longer reflects the evidence or the practice of a growing number of countries, but in developing a framework that balances national sovereignty with international cooperation, criminal enforcement against trafficking with public health responses to use, and legitimate concerns about drug-related harm with the evidence that prohibition itself generates harms that alternative approaches can reduce. The comparative study of international drug policy provides the analytical foundation for this transformation, demonstrating that evidence-based reform is not only possible but already underway across the globe.
Conclusion
International approaches to drug policy reveal a global governance system in transition. The UN drug control conventions established a prohibition framework that achieved near-universal ratification and shaped domestic policy for more than half a century. This framework is now challenged by national experiments—decriminalization in Portugal, cannabis legalization in Canada and Uruguay, harm reduction across Europe—that test treaty boundaries and generate evidence that alternatives can produce superior outcomes on public health, criminal justice, and social equity indicators.
The tension between the conventions and the evidence cannot be sustained indefinitely. Either the conventions will be formally revised to accommodate diverse practices, or they will be informally eroded through non-compliance until their practical significance diminishes. The comparative evidence points toward a future guided more by public health evidence and less by prohibition orthodoxy—one in which the international framework supports national policy experimentation while maintaining cooperative mechanisms for the truly transnational dimensions of drug markets.
The path to this future runs through the accumulation of evidence from national experiments, its dissemination through international forums, and the gradual building of political consensus for reform. The comparative study of international drug policy demonstrates that this process is well underway and that the direction of change, while contested, is increasingly clear.
References
- Bewley-Taylor, D. R. (2012). International drug control: Consensus fractured. Cambridge University Press.
- Caulkins, J. P., Kilmer, B., & Kleiman, M. A. R. (2016). Marijuana legalization (2nd ed.). Oxford University Press.
- Cerdá, M., et al. (2020). Association between recreational marijuana legalization and changes in marijuana use. JAMA Psychiatry, 77(2), 165–171.
- Csete, J., et al. (2016). Public health and international drug policy. The Lancet, 387(10026), 1427–1480.
- Fischer, B., Lee, A., Robinson, T., & Hall, W. (2020). Cannabis use indicators pre- and post-legalization in Canada. Substance Abuse Treatment, Prevention, and Policy, 15(1), 74.
- Greenwald, G. (2009). Drug decriminalization in Portugal. Cato Institute.
- Hughes, C. E., & Stevens, A. (2010). What can we learn from the Portuguese decriminalization? British Journal of Criminology, 50(6), 999–1022.
- INCB. (2023). Annual Report 2022. International Narcotics Control Board.
- Kolodny, A., et al. (2015). The prescription opioid and heroin crisis. Annual Review of Public Health, 36, 559–574.
- MacCoun, R. J., & Reuter, P. (2001). Drug war heresies. Cambridge University Press.
- Potier, C., et al. (2014). Supervised injection services. Drug and Alcohol Dependence, 145, 48–68.
- Rehm, J., et al. (2001). Feasibility, safety, and efficacy of injectable heroin prescription. The Lancet, 358(9291), 1417–1423.
- Reuter, P. (2013). Why has US drug policy changed so little? Crime and Justice, 42(1), 75–140.
- Room, R. (2012). Reform by subtraction. International Journal of Drug Policy, 23(5), 401–406.
- Stevens, A. (2011). Drugs, crime and public health. Routledge.
- Transform Drug Policy Foundation. (2009). After the war on drugs: Blueprint for regulation. Transform.
- UNODC. (2022). World Drug Report 2022. UNODC.
- Youngers, C. A., & Rosin, E. (Eds.). (2005). Drugs and democracy in Latin America. Lynne Rienner Publishers.
- Babor, T. F., et al. (2018). Drug policy and the public good (2nd ed.). Oxford University Press.
- Rolles, S. (2012). After the war on drugs: Options for control. Transform Drug Policy Foundation.
- Murkin, G. (2014). Drug decriminalisation in Portugal: Setting the record straight. Transform Drug Policy Foundation.
- Hall, W., & Lynskey, M. (2016). Evaluating the public health impacts of legalizing recreational cannabis use. Addiction, 111(10), 1764–1773.
- Pacula, R. L., & Smart, R. (2017). Medical marijuana and marijuana legalization. Annual Review of Clinical Psychology, 13, 397–419.
- Chatwin, C. (2011). Drug policy harmonization and the European Union. Palgrave Macmillan.
- Lines, R. (2017). Drug control and human rights in international law. Cambridge University Press.
- Werb, D., et al. (2011). Effect of drug law enforcement on drug market violence. International Journal of Drug Policy, 22(2), 87–94.
- Degenhardt, L., et al. (2008). Toward a global view of alcohol, tobacco, cannabis, and cocaine use. PLoS Medicine, 5(7), e141.
- Eastwood, N., Shiner, M., & Bear, D. (2016). The numbers in black and white: Ethnic disparities in the policing and prosecution of drug offences in England and Wales. Release.
- Seddon, T. (2010). A history of drugs. Routledge.
- Trace, M., Roberts, M., & Klein, A. (2004). Reclassification of cannabis in the United Kingdom. Beckley Foundation Drug Policy Programme.
Related Articles
- Comparative Drug Policy
- International Drug Trafficking
- International Crime Conventions and Treaties
- Lessons for U.S. Criminal Justice from Comparative Research